Giving

Thank you for considering a donation to the Bridges to Better Medicine Initiative. Your gift will help support:

Technology Innovation Fund:  The private sector prefers to invest in the commercial development of discoveries and technologies that will have a positive impact for the consumer, but the "proof of principle" studies required to demonstrate commercial potential are rarely conducted by academic scientists, due to the lack of an established funding mechanism for this purpose. This results in a development gap between early-stage academic invention and validation at a level that will attract the participation of the private sector. The Technology Innovation Fund aims to bridge this gap by providing investigators with grants that will allow them to conduct "proof of principle" and pre-clinical studies. The goal of the Fund is to break down barriers to industry licensing or funding of start-ups based on Rockefeller technology. Grants from the Fund are used by Rockefeller laboratory heads in numerous ways, for example, to develop the extra experimental data needed to ensure a successful patent application, or to demonstrate an invention's promise in the health field for companies and investors.

Underwriting Bridges to Better Medicine:  Companies and individuals in the life science business community – including pharmaceutical and biotechnology firms, healthcare investment firms, and venture capital firms, and their employees – can provide underwriting gifts for the Bridges to Better Medicine Initiative.  Underwriters will receive recognition on the Bridges website and in printed materials.

Postdoctoral Fellowships:  Founded in 1901, Rockefeller was the first U.S. institution to offer postdoctoral training to outstanding young investigators, preparing them for productive careers in the biomedical and related sciences. Today, more than 350 postdoctoral scientists are at work in the University's laboratories, where they make key contributions to the research enterprise. Postdoctoral Fellowships will provide salary support to exceptional young scientists who seek to conduct innovative, risk-taking studies, with an emphasis on translational research.



To discuss making a gift please contact: 

Support Bridges to Better MedicineLisa Kressbach
The Rockefeller University
1230 York Avenue, Box 164
New York, NY 10065
Telephone: (212) 327-8961
E-mail: Lisa.Kressbach@rockefeller.edu

 

The Rockefeller University is a tax-exempt charitable organization as described in Section 501(c)(3) and Section 509(a)(1) of the Internal Revenue Code. Contributions to the University are deductible for federal income and gift tax purposes as provided in Sections 170 and 2522 of the Internal Revenue Code. Gifts to the University under a donor’s will are deductible for federal estate tax purposes as provided in Section 2055 of the Internal Revenue Code.

Marc Tessier-Lavigne, Ph.D.
President
The Rockefeller University

Moderator

Barry Coller, M.D.
Vice President for Medical Affairs and Physician-in-Chief
The Rockefeller University

Director
Center for Clinical and Translational Science

Co-Chairs

Anthony B. Evnin, Ph.D.
General Partner
Venrock

Robin Chemers Neustein
Senior Director
Goldman, Sachs & Co.

Steering Committee

Ron Cohen, M.D.
Acorda Therapeutics

Kathleen Denis, Ph.D.
The Rockefeller University

David Elliman
Elmrock Capital

Emilio Emini, Ph.D.
Pfizer

Teena Lerner, Ph.D.
Rx Capital Management

Paul Maddon, M.D., Ph.D.
Progenics Pharmaceuticals

Brad Margus
Envoy Therapeutics

Sharon Mates, Ph.D.
Intra-Cellular Therapies

Robin Chemers Neustein
Goldman, Sachs & Co.

Russell Pennoyer
Benedetto, Gartland & Co.

Geoff Smith
Ascent Biomedical Ventures

George Yancopoulos, M.D., Ph.D.
Regeneron Pharmaceuticals

bridges@rockefeller.edu

RSS Facebook Twitter YouTube

The Rockefeller University | 1230 York Avenue, New York, NY 10065 | 212-327-8000
Copyright © 2004–2013 The Rockefeller University. All rights reserved.
Contact | Comments | Site Map | Copyright Complaints | Mobile Site | Privacy Policy